Home
About BCG
Contact Us
Locations
Services
Areas of Expertise
Regulatory Library
Newsletter Archive
Useful Web Links
Presentations
 

 

 

 

 

 

 

 

   

SPECIAL EXPERTISE :

Preclinical program management, preparation of US FDA regulatory IND submissions to allow entry into the clinic and set-up and management of Phase I and II clinical trials.

Over 10 years of clinical trials experience. Therapeutic areas of experience include HIV, HBV, bacterial infection and autoimmune and renal disease, encompassing the development of both small molecule and biologic products.

PROGRAM MANAGEMENT EXPERIENCE
  • Provided project direction, leadership for the preclinical toxicology assessment, manufacture and clinical development of biopharmaceutical products.
  • Identified product development strategies, risk and provided options to limit risk.
  • Identified critical tasks and resources.
  • Ensured that the project timeline was met and the quality of work maintained in a cost effective manner.
  • Prepared and negotiated contracts with contractors resulting in substantial cost savings to the Sponsor.
  • Prepared budget proposals, organized resources and tracked resource usage, prepared and maintained Gantt charts.
  • Organized and led project team meetings.
  • Managed and developed an excellent working relationship with contractors (CROs, CMOs, Contract Laboratories, Data management contractors) with considerable positive feedback
REGULATORY AFFAIRS EXPERIENCE
  • Assessed biopharmaceutical products and platform technologies including:
    • Assessment of preclinical data, CMC data, clinical trial design and study protocols.
    • Literature review of scientific and clinical information.
    • Review of grant applications.
  • Assisted in the identification and preparation of an appropriate regulatory strategy, product development plan and clinical development plan (CDP).
  • Contributed to design of preclinical pharmacodynamic and toxicology studies.
  • Authored FDA pre-IND meeting and IND submissions, which included:
    • Preclinical pharmacology and toxicology section.
    • Clinical section; CDP, study protocols, Investigator's Brochure.
    • CMC information; GMP manufacture.
    • Prepared FDA meeting request letters.
    • Correspond with FDA reviewers.
  • Prepared FDA IND amendments.
  • Searched and interpreted FDA guidelines.
  • Reviewed Biologic Master Files.
  • Provided QA function:
    • Review of SOPs.
    • GLP training.
    • Review of preclinical study design, protocols and batch records.
    • Review of research study conduct.
CLINICAL EXPERIENCE
  • Project Management:
    • Provided clinical project management for single and multi-site Phase I and II studies in the US and Australia.
    • Led clinical trial team of regulatory and clinical experts.
    • Directly supervised CRAs.
  • Study Set-up:
    • Designed and/or authored (phase I/II) protocols and Case Report Forms (CRFs), Regulatory and Master File essential documents, Clinical Monitoring Plans, Study Manuals and Monitoring Guidelines.
    • Organized and presented at investigator meetings.
    • Prepared Institutional Review Board (IRB) applications including informed consent (ICF) documents.
    • Initiated sites; visited sites to prepare staff for conducting studies and enrolling subjects.
    • Trained CRAs and study coordinators.
    • Planned the supply, randomization procedure and dispensing of investigational agent (study product).
  • Site Selection:
    • Prepared RFPs for study sites and reviewed proposals.
    • Identified and recruited potential investigators and evaluated sites.
    • Constructed clinical trial budgets and reviewed site budget proposals.
    • Negotiated site budgets to minimize Sponsor costs.
  • Ongoing Study Management:
    • Identified recruitment strategies and improved subject recruitment.
    • Communicated with investigators, developed and maintained strong working relationship with investigator and study coordinators.
    • Managed study sites, ensured ongoing prospective assessment of study issues, and took corrective action where required.
    • Monitored sites and verified the integrity of clinical data.
    • Ensured that sites were conducting studies in accordance with the protocol, GCP, ICH and FDA guidelines.
    • Tracked study progress and improved site performance by ongoing review of study data (review of Data Management tracking tools) and follow-up with CRAs, investigators and coordinators to take corrective action.
    • Generated study newsletters, progress and meeting reports.
CELL BIOLOGY, CELLULAR IMMUNOLOGY EXPERIENCE
  • Contributed to the overall team development of a peptide vaccine, for the treatment of patients chronically infected with Hepatitis B virus.
  • Prepared detailed technical reports and scientific papers.
  • Analyzed and interpreted results.
  • Developed problem-solving skills.
  • Devised hypotheses and planned research projects.
  • Developed Bioassays

EDUCATION

Ph.D.   University of Melbourne, Walter and Eliza Hall Institute for Medical Research, Melbourne, Australia (1987-1990)
M.App.Sc.   Cancer Institute, Peter MacCallum Hospital, Melbourne, Australia (1983-1985)
B.App.Sc. Swinburne Institute, Biochemistry and Chemistry (1979-1982)

HONORS AND AWARDS:

2001   Excellence award, CSG diabetic nephropathy trial
1993   Cytel Financial Award, for contribution to the HBV project
1987-1990   University of Melbourne Postgraduate Scholarship

EXPERIENCE:

CURRENT POSITION:
2002 to present:

Consultant, Biologics Consulting Group Inc.
San Mateo, CA USA (Sept. 2002 - present)

   
Sept 1999 to Sept 2002   Clinical Research Associate, Laboratories Fournier SA, Bondi Junction, NSW Australia.
   
May 1997 to Dec 2000  

Pacific Project Coordinator, Collaborative Study Group, Monash Medical Centre, Melbourne, Australia.

   
Aug. 1996 to Dec. 1996  

Project Manager, Narhex Operations Pty. Ltd., Sydney, Australia.

   
Dec. 1994 to July 1996  

Business Manager , VYMP Pty. Ltd., Melbourne, Australia.

   
Mar. 1994 to Nov. 1994  

Clinical Trial Coordinator, Western Hospital, Melbourne, Australia.

   
Jan. 1992 to Jun. 1993  

Postdoctoral Research Scientist, Cytel Corporation, San Diego, CA.

   
Jan 1991 to Dec. 1991   Postdoctoral Research Scientist, Whittier Institute, Scripps Hospital, San Diego, CA.

BIBLIOGRAPHY:
1.   Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari, FV, Furze J, Bartholomeusz R, Chesnut, RW. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest. 1995 Jan; 95(1):341-9.
   
2.   Kielczynski W, Bartholomeusz RK, Harrison LC. Characterization of ganglioside associated with the thyrotrophin receptor. Glycobiology. 1994 Dec;4(6):791 6.
   
3.   Allison J, Malcolm L, Culvenor J, Bartholomeusz RK, Holmberg K, Miller JF. Overexpression of beta 2 microglobulin in transgenic mouse islet beta cells results in defective insulin secretion. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2070 4.
   
4.   Bartholomeusz RK, Campbell IL, Harrison LC. A2135 reactive ganglioside expression determines the differentiation stage and capacity of rat insulinoma (RIN) sublines. Cell Differ Dev. 1990 Oct;32(1):39 46.
   
5.   Bartholomeusz RK, Campbell IL, Harrison LC. A2135 reactive ganglioside expression is an index of differentiation in rat insulinoma (RIN) cells. Endocrinology. 1990 Apr;126(4):1927 33.
   
6.   Bartholomeusz RK, Campbell IL, Harrison LC. Pancreatic islet A2B5 and 3G5 reactive gangliosides are markers of differentiation in rat insulinoma cells. Endocrinology. 1989 Jun;124(6):2680 5.
   
7.   Bartholomeusz RK, Bertoncello I, Chamley WA. A correlation between ovarian follicular maturity and anchorage independent growth of bovine granulosa cells. Int J Cell Cloning. 1988 Mar; 6(2):106 15.
   
8.   Bartholomeusz RK, Bertoncello 1. Anchorage independence as an index of proliferative potential and maturational age: a comparison of the growth of normal, primary explanted bovine granulosa cells in semisolid agar and in liquid culture. Int J Cell Cloning. 1987 Mar;5(2):142 8.
   
9.   Type I diabetes: Immunopathology and Immunotherapy. Harrison LC, Campbell IL, Colman PG, Chosich N, Kay TW, Tait BD, Bartholomeusz RK, DeAizpurua HJ, Joseph JL, Chu S and Kielczynski WE. In Advances in Endocrinology and Metabolism. Eds. EL Mazzaferri, RS Bar and RA Kreisberg. Voll, 1990, p36 94. (Mosby Year Book Inc)
   
Page Updated: October 3, 2007